References
- Owen DR, Wood DM, Archer JR, et al. Phenibut (4-amino-3-phenyl-butyric acid): availability, prevalence of use, desired effects and acute toxicity. Drug Alcohol Rev. 2016;35(5):591–596. doi: 10.1111/dar.12356.
- Todd DA, Kellogg JJ, Wallace ED, et al. Chemical composition and biological effects of kratom (mitragyna speciosa): in vitro studies with implications for efficacy and drug interactions. Sci Rep. 2020;10(1):19158. doi: 10.1038/s41598-020-76119-w.
- Trakulsrichai S, Sathirakul K, Auparakkitanon S, et al. Pharmacokinetics of mitragynine in man. Drug Des Devel Ther. 2015;9:2421–2429.
- Tanna RS, Nguyen JT, Hadi DL, et al. Clinical pharmacokinetic assessment of kratom (mitragyna speciosa), a botanical product with opioid-like effects, in healthy adult participants. Pharmaceutics. 2022;14(3):620. doi: 10.3390/pharmaceutics14030620.
- Lapin I. Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug. CNS Drug Rev. 2001;7(4):471–481. doi: 10.1111/j.1527-3458.2001.tb00211.x.